Drug Discovery World

MAY 1, 2024

A drop in the prices of non-human primates (NHPs) in China indicates a post-pandemic slowdown in Chinese drug development, according to a report in the Financial Times. Data provider Pharmcube reported that investment on new drug discovery in China fell by 32% in 2023 to $4.8 The figures are taken from UBS data.

Vaccine 130

Vaccine Pharmaceuticals Drug Development Research 130

Drug Discovery World

SEPTEMBER 26, 2022

DDW Editor Reece Armstrong explores the rise of drug repurposing and the benefits and disadvantages it brings to drug discovery and development. . Drug repurposing, the act of finding new clinical targets for both approved and unapproved drugs, has emerged as a viable alternative to traditional drug discovery approaches. .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Discovery World

MARCH 13, 2024

According to Statista, revenue in this sector is expected to grow at an annual rate of 6.77%, resulting in a market volume of US$2,208m by 2028 1. Singapore is among a few countries worldwide whose pharmaceutical export value far exceed the import value.

Government 173

Government Science Pharmaceuticals Vaccine 173

DrugBank

AUGUST 9, 2024

Investment Trends in Pharmaceutical Research and Development Investing in the pharmaceutical sector presents a unique set of challenges and opportunities; let’s examine them in more detail.    The average cost of bringing a new drug to market is about $2.6 trillion by 2028. trillion by 2028.

Pharmaceuticals 76

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 76

Codon

SEPTEMBER 29, 2024

The earliest ones relied on simple linear regression and attempted to correlate genetic variations with observable traits or disease risks — such as drug metabolization rates or cancer susceptibility. 2028 Over the next year, the scientific community ferociously interrogated the model.

Engineering 125

Engineering Virus DNA Therapies 125

Agency IQ

FEBRUARY 2, 2024

There are also continued questions about regulatory capacity and what the field will look like going forward, with implications for drug developers who rely on diagnostic products. A sea change for lab tests, the implications for drug developers and outstanding questions about endpoints In the U.S.,

FDA 40

FDA Regulations Laboratories Production 40